Echo IQ Limited (ASX:EIQ), the AI and medical technology company focused on cardiac diagnostics, is trading at AUD 0.55 on 29 September 2026, up 2.22% on the day. The stock has been navigating a challenging regulatory situation following the US Food and Drug Administration's Not Substantially Equivalent (NSE) determination on its initial EchoSolv HF 510(k) clearance application. However, management's update on 17 September 2026 outlines a confident pathway forward — multiple regulatory routes remain open, and the company believes clearance remains achievable under the 510(k) route based on its review of the FDA's specific concerns.

About the Company

Echo IQ Limited is an Australian AI and medical technology company developing artificial intelligence-based tools for the diagnosis and management of heart failure using echocardiography. Its flagship product, EchoSolv HF, is designed to analyse echocardiographic data to assist clinicians in identifying and characterising heart failure. The company is pursuing FDA clearance in the United States — the world's largest medical device market — as a cornerstone of its commercialisation strategy, alongside strategic partner agreements that the company notes have not been materially impacted by the regulatory activity.

Recent Development

In an ASX announcement dated 17 September 2026, Echo IQ provided an update on its engagement with the FDA following the issuance of an NSE determination on its initial EchoSolv HF 510(k) application. Echo IQ reviewed the FDA's determination and concluded that the matters cited were limited to aspects of statistical analysis supporting the clinical validation — not to any concern about the underlying technology or core functionality of EchoSolv HF. The company identified multiple potential pathways to progress EchoSolv HF towards FDA clearance: an administrative appeal of the NSE determination (which could potentially be resolved in under 90 days and might result in the determination being overturned or the FDA reopening its review); a review through the FDA Ombudsman (which can assist with procedural review of the NSE determination); or a new 510(k) submission. The company stated it believes there is a clear path forward to obtaining FDA clearance for EchoSolv HF and that clearance could potentially be achieved over the coming quarters. The company also confirmed that strategic partner agreements have not been materially impacted by the regulatory activity.

Sector Context

AI-assisted cardiac diagnostics is one of the most rapidly advancing areas of medical technology, with multiple companies globally developing Machine Learning tools to assist clinicians in interpreting echocardiographic, electrocardiographic, and other cardiac imaging data. Heart failure — the condition that EchoSolv HF targets — affects an estimated 64 million people globally and represents a major clinical and economic burden. FDA clearance is the gold standard for market access in the United States, and a 510(k) clearance pathway (which requires demonstration of substantial equivalence to a predicate device) is the standard route for devices of this type. The statistical analysis issues cited by the FDA are not unusual regulatory challenges for AI medical device submissions, where clinical validation methodologies are still evolving.

Risks and Uncertainty

An NSE determination is a meaningful regulatory setback, even if the company is confident of the available pathways forward. Administrative appeals can have uncertain timelines — the '90 days or less' scenario is optimistic but not guaranteed. A new 510(k) submission would require collecting additional clinical data or revising the statistical analysis, potentially taking 12 months or more to prepare and process. The company's commercial trajectory depends heavily on US market access, meaning any prolonged regulatory delay would impact Revenue timelines. Strategic partners who may be evaluating integration of EchoSolv HF into their platforms or workflows may pause decisions pending FDA clearance.

Catalysts to Watch

The company's chosen pathway for addressing the FDA's NSE determination — administrative appeal, FDA Ombudsman review, or new 510(k) submission — will be the most watched near-term update. An administrative appeal, if pursued, could provide a result within 90 days, making this the fastest potential pathway to clearance. Any confirmation of FDA clearance for EchoSolv HF would be a transformational catalyst for Echo IQ, enabling US market commercialisation and potentially accelerating strategic partner negotiations. Updates on the status and performance of existing strategic partner agreements will also be relevant for assessing the company's near-term commercial trajectory.